AI Drug Discovery Leaders Gain a Competitive Edge with Telesis Bio’s Gibson SOLA® Platform, Generating Development Candidates Faster
Telesis Bio® Inc., maker of the world’s only intelligent, on-premises DNA synthesis solution for AI labs, today announced recent commercial licensing agreements with several AI-native drug discovery companies. The agreements reflect a growing understanding that integrating automated high-throughput DNA synthesis directly into the laboratory is necessary to enable true closed-loop AI drug discovery and drive the rapid advancement of AI models.
